Last Updated : Monday, September 9, 2019 20:29:43

LUPIN gets USFDA nod to market drug to treat Heart, Liver & Kidney disorders

BALTIMORE (US) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Mumbai headquartered pharma company Lupin Ltd said of having got USFDA nod to market drug to treat heart, liver and kidney related disorders.

In a press-communication submitted to the Indian Bourses, titled – “Lupin receives U.S. FDA approval for Ethacrynic Acid Tablets USP” read that, Pharma major Lupin Limited (Lupin) announced that it has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (U.S. FDA).

Lupin’s Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin® Tablets, 25 mg, of Bausch Health Americas, Inc.

It is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.

  • Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
  • Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
  • Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
  • Intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.

Ethacrynic Acid Tablets USP (RLD: Edecrin® Tablets) had annual sales of approximately USD 24 million in the US (IQVIA MAT June 2019).


FacebookLinkedinTwitterYouTube, Blogspot, Telegram, Instagram 

You can also access and/or read the above narrated news-report on our : BLOG and/or WEBSITE.


Do NOT follow this link or you will be banned from the site!